uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Klinisk farmakogenomik och osteoporos.ORCID-id: 0000-0002-6368-2622
Vise andre og tillknytning
Ansvarlig organisasjon
2005 (engelsk)Inngår i: The Pharmacogenomics Journal, ISSN 1470-269X, E-ISSN 1473-1150, Vol. 5, nr 4, s. 262-70Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

We report a novel combination of factors that explains almost 60% of variable response to warfarin. Warfarin is a widely used anticoagulant, which acts through interference with vitamin K epoxide reductase that is encoded by VKORC1. In the next step of the vitamin K cycle, gamma-glutamyl carboxylase encoded by GGCX uses reduced vitamin K to activate clotting factors. We genotyped 201 warfarin-treated patients for common polymorphisms in VKORC1 and GGCX. All the five VKORC1 single-nucleotide polymorphisms covary significantly with warfarin dose, and explain 29-30% of variance in dose. Thus, VKORC1 has a larger impact than cytochrome P450 2C9, which explains 12% of variance in dose. In addition, one GGCX SNP showed a small but significant effect on warfarin dose. Incorrect dosage, especially during the initial phase of treatment, carries a high risk of either severe bleeding or failure to prevent thromboembolism. Genotype-based dose predictions may in future enable personalised drug treatment from the start of warfarin therapy.The Pharmacogenomics Journal advance online publication, 10 May 2005; doi:10.1038/sj.tpj.6500313.

sted, utgiver, år, opplag, sider
2005. Vol. 5, nr 4, s. 262-70
Emneord [en]
warfarin, VKORC1, CYP2C9, pharmacogenomics, GGCX
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-72916DOI: 10.1038/sj.tpj.6500313PubMedID: 15883587OAI: oai:DiVA.org:uu-72916DiVA, id: diva2:100827
Tilgjengelig fra: 2008-08-29 Laget: 2009-03-24 Sist oppdatert: 2018-01-14

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=15883587&dopt=Citation

Personposter BETA

Wadelius, MiaEriksson, NiclasWallerman, OlaMelhus, HåkanWadelius, Claes

Søk i DiVA

Av forfatter/redaktør
Wadelius, MiaEriksson, NiclasWallerman, OlaMelhus, HåkanWadelius, Claes
Av organisasjonen
I samme tidsskrift
The Pharmacogenomics Journal

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 831 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf